Clairity has received FDA de novo authorization for Clarity Breast, an AI tool that predicts five-year breast cancer risk from screening mammograms.
Key Details
- 1Clairity Breast predicts future breast cancer risk using AI analysis of 2D screening mammograms.
- 2FDA de novo authorization has been granted for the software platform.
- 3The AI model was trained on 450,000+ mammograms and validated on 77,000 exams with five-year follow-up data.
- 4Unlike CAD tools, the software provides a risk percentage for patients rather than assisting real-time interpretation.
- 5Models were developed for diverse populations, addressing historic limitations in risk prediction for non-European ancestry.
- 6Currently available for Hologic mammography systems, with future plans for multivendor and 3D support.
Why It Matters
This represents a significant advance in leveraging mammogram images beyond immediate diagnosis, opening new avenues for personalized risk assessment in breast imaging. The FDA clearance and focus on diversity in model training mark meaningful steps toward broader clinical adoption and equity.
Source
AuntMinnie
Related News
•Radiology Business
RadNet and Desert Oasis Launch No-Cost AI Breast Cancer Screening
RadNet partners with Desert Oasis Healthcare to provide AI-enhanced breast cancer detection at no extra cost.
•Radiology Business
Women's Uncertainty About AI in Breast Imaging May Limit Acceptance
Many women remain unclear about the role of AI in breast imaging, creating hesitation toward its adoption.
•Radiology Business
Harrison.ai Receives FDA Breakthrough Status for Imaging AI Device
Harrison.ai has been awarded three FDA breakthrough device designations for its imaging AI solutions, including a tool for obstructive hydrocephalus triage.